SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is surging alongside other semiconductor leaders as strong CPU performance data from Intel drives sector-wide momentum and investor FOMO. The community is actively debating whether this parabolic rally is a sustainable AI-driven breakout or an overextended bubble, with many traders focused on short squeezes and aggressive price action.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is rallying on massive volume as investors react to the company's expanding role in AI infrastructure, specifically following confirmation of orders linked to Marvell and potential integration into hyperscale ecosystems. The community is actively celebrating a significant short squeeze, with many long-term shareholders highlighting the company's move from R&D to commercial execution as a major long-term catalyst.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera is seeing a surge in investor attention as the community anticipates news regarding potential Joint Development Agreements and commercial licensing deals tied to its Mears Silicon Technology, particularly within the Gate-All-Around and DRAM sectors. Traders are closely monitoring the stock's significant volume and price volatility, driven by speculation over partnerships with major semiconductor foundries and equipment manufacturers amid a broader focus on AI infrastructure.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is currently trending as retail investors react to a recent convertible notes offering, which triggered short-term volatility despite analysts viewing it as a move to strengthen the company's balance sheet for long-term R&D. The community remains deeply divided, with many long-term holders expressing frustration over price stagnation and leadership execution, while others highlight the company's $2 billion cash pile and upcoming clinical data catalysts as reasons to remain bullish.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is experiencing significant volatility and downward pressure as shareholders react to a recent shelf offering and concerns over clinical trial timelines. While the community remains polarized, with some investors accumulating shares on dips anticipating future trial data and a potential short squeeze, others are expressing frustration over the persistent selling and lack of clear upward momentum.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is facing a sharp sell-off as investors react to margin concerns and geopolitical headwinds, despite the company beating revenue expectations and raising its AI-driven growth targets. Community sentiment is deeply divided between long-term investors viewing the pullback as a generational buying opportunity and traders expressing frustration over extreme volatility and the broader rotation of capital away from enterprise software.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is gaining momentum as investors eye upcoming industry events and potential integration news, with the community actively debating the project's utility versus broader market volatility. Enthusiasts are focusing on long-term growth and technical accumulation, while discussion remains divided between those expecting significant adoption and others expressing caution over price trends.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

The VanEck Semiconductor ETF is experiencing intense volatility and record-breaking momentum, with community debate centered on whether this surge represents a sustainable AI-driven growth cycle or a speculative bubble reminiscent of the dot-com era. Traders are actively discussing the extreme technical overextension and concentration of the trade, with many weighing the risks of a blow-off top against the potential for continued upside from data center demand.

MaxLinear, Inc. engages in the provision of communications systems-on-chip (SoC) solutions used in broadband, mobile and wireline infrastructure, data center, and industrial and multi-market applications. Its products include cable broadband modems and gateways, wireline connectivity devices, radio frequency transceivers, fiber-optic modules, video set-top boxes and gateways, hybrid analog and digital televisions, direct broadcast satellite outdoor and indoor units, and power management and interface products. The company was founded by Kimihiko Imura, Curtis C. Ling, and Kishore V. Seendripu on September 25, 2003 and is headquartered in Carlsbad, CA.

MaxLinear Inc

MaxLinear is currently trending as retail traders and momentum investors navigate the volatility following a major Q1 earnings beat and significant sector rotation into data center infrastructure. The community is actively debating whether this parabolic move is a sustainable re-rating driven by AI-related optical demand or a potential short squeeze that leaves the stock vulnerable to profit-taking and technical exhaustion.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

The iShares Semiconductor ETF (SOXX) has captured significant community attention due to its historic streak of consecutive green sessions and parabolic price action, prompting intense debate over whether it represents a sustainable AI-driven bull run or an overdue blow-off top. Investors are actively discussing the risks of extreme overbought conditions while weighing tactical hedging strategies, such as using inverse ETFs, against a bullish narrative centered on unrelenting demand for AI infrastructure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Evotec (NASDAQ:EVO) Sees Strong Trading Volume  - Should You Buy?

Evotec (NASDAQ:EVO) Sees Large Volume Increase - What's Next...

Evotec CFO Paul Hitchin Resigns; Names Claire Hinshelwood Replacement

(RTTNews) - Evotec SE (EVO, EVTG.DE, EVTCY.PK), a life science company, announced Friday that its CFO Paul Hitchin will leave the company on April 30, "citing personal reasons unrelated to Evotec...

Evotec (NASDAQ:EVO) Shares Gap Down - Should You Sell?

Evotec (NASDAQ:EVO) Shares Gap Down - Here's What Happened...

Evotec (NASDAQ:EVO) Shares Gap Up   - Here's What Happened

Evotec (NASDAQ:EVO) Shares Gap Up - Should You Buy...

What is HC Wainwright's Forecast for Evotec Q1 Earnings?

Evotec AG (NASDAQ:EVO - Free Report) - HC Wainwright issued their Q1 2026 earnings per share estimates for Evotec in a research report issued to clients and investors on Wednesday, April 15th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings of ($0.11) per share for...

Evotec AG (NASDAQ:EVO) Given Average Rating of "Hold" by Brokerages

Evotec AG (NASDAQ:EVO - Get Free Report) has received a consensus rating of "Hold" from the five research firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three...

Short Interest in Evotec AG (NASDAQ:EVO) Declines By 15.1%

Evotec AG (NASDAQ:EVO - Get Free Report) saw a significant drop in short interest in March. As of March 31st, there was short interest totaling 349,478 shares, a drop of 15.1% from the March 15th total of 411,580 shares. Based on an average daily volume of 113,394 shares, the short-interest ratio...

Equities Analysts Issue Forecasts for Evotec FY2030 Earnings

Evotec AG (NASDAQ:EVO - Free Report) - Stock analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Evotec in a research note issued on Wednesday, April 15th. HC...

Evotec (NASDAQ:EVO) Now Covered by Analysts at HC Wainwright

HC Wainwright assumed coverage on shares of Evotec in a research report on Wednesday. They issued a "buy" rating and a $7.00 target price for the company...

Evotec (NASDAQ:EVO) Shares Gap Up   - Should You Buy?

Evotec (NASDAQ:EVO) Shares Gap Up - Here's Why...

Evotec SE is a life science company, which engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the Shared R&D and Just–Evotec Biologics segments. The Shared R&D segment includes drug discovery and development services and solutions. The Just–Evotec Biologics segment provides services related to designing, discovering, developing, and manufacturing of modern biotherapeutics. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, Charles Weissmann, and Nobel Laureate on December 8, 1993 and is headquartered in Hamburg, Germany.

Current Price	$3.16
Prev Close	$3.23
Open	$3.06
Dividend Yield	0.00%
50-Day Moving Average	$2.93
Beta	1.05
Avg. Volume	133,617.17
PE Ratio	-9.90

52-Week High	$4.80
52-Week Low	$2.31
Market Capitalization	$1.15B
EPS (Annual)	-$0.3289
Price to Book	1.20
Revenue Per Employee	$195,418.49

EVO
Eaton Vance Ohio Municipal Income Trust

Feed

News

Sentiment

Fundamentals

Info

Latest EVO News

EVOEaton Vance Ohio Municipal Income Trust